Non-Hodgkin Lymphoma Treatment Market Size, Share & Industry Analysis, By Therapy (Immunotherapy, Targeted Therapy, Chemotherapy, and Others), By Disease Type (B-cell Lymphoma, and T-cell Lymphoma), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies & Drug Stores, and Online Pharmacies), and Regional Forecast, 2019-2026 (Includes COVID-19 Business Impact)

                                          
We have updated Non-Hodgkin Lymphoma Treatment Market with respect to COVID-19 Business Impact.
Inquire before buying


This report focuses on the Non-Hodgkin Lymphoma Treatment market and value at the global level, regional level, and company level. From a global perspective, this report represents the overall Non-Hodgkin Lymphoma Treatment market size by analyzing historical data and future prospects. Regionally, this report focuses on several key regions: North America, Europe, Japan, China, Southeast Asia, India, Latin America, and South America.


Global Non-Hodgkin Lymphoma Treatment Market: Segment Analysis


The research report includes specific segments by region (country), by Company, by Type, and by Application. This study provides information about the sales and revenue during the historic and forecasted period of 2019 to 2029. An in-depth analysis of the segments assists in identifying the different factors that will aid market growth.


Global Non-Hodgkin Lymphoma Treatment Market: Regional Analysis


The research report includes a detailed study of regions of North America, Europe, Japan, China, Southeast Asia, India, Latin America, and South America. The report has been curated after observing and studying various factors that determine regional growth such as the economic, environmental, social, technological, and political status of the particular region. Researchers have studied the data of revenue, sales, and manufacturers of each mentioned region. This section analyses region-wise revenue and volume for the forecast period of 2019 to 2029.


Global Non-Hodgkin Lymphoma Treatment Market: Competitive Landscape


This section of the report identifies various key manufacturers of the market. It helps the reader understand the strategies and collaborations that players are focusing on combat competition in the market. The comprehensive report provides a significant microscopic look at the market. The reader can identify the footprints of the manufacturers by knowing about the global revenue of manufacturers, the global price of manufacturers, and sales by manufacturers during the forecast period of 2019 to 2029.
List of Companies Profiled

Strong and Key Product Offerings Coupled with Core Focus on Oncology of Major Players, to Augment the Global Market GrowthLike many other oncology markets, the global non-Hodgkin therapeutics market reflects an intensely competitive scene with several oncology market giants vying for a strong market presence. Several of the major pharmaceutical giants in oncology such as Novartis AG and Gilead Sciences, Inc. have significant market shares. These companies have advanced and sophisticated therapies such as targeted therapies and immunotherapies, which are significantly more expensive from generic therapies. This leads to a strong revenue position for these pharmaceutical companies, leading to a strong market presence.On the other hand, companies such as Spectrum Pharmaceuticals, Inc., are making their presence noticeable in the global market with their focused product portfolio which has a number of key therapeutics for non-Hodgkins lymphoma. This is anticipated to have a positive impact on the global market as these companies are expected to gain market share during the forecast period through increase in market presence and launch of new therapeutics.

LIST OF KEY COMPANIES PROFILED:

Takeda Pharmaceutical Company LimitedAstraZenecaBayer AGNovartis AGKite Pharma, Inc. / Gilead Sciences, Inc.Spectrum Pharmaceuticals, Inc.Teva Pharmaceutical Industries Ltd.Bristol Myers Squibb CompanyJanssen Pharmaceuticals, Inc.Genentech, Inc. (F. Hoffmann-La Roche Ltd)CELGENE CORPORATION (Bristol Myers Squibb Company)Merck & Co., Inc.Kyowa Kirin Co., Ltd.AbbVie Inc.SanofiOthers

KEY INDUSTRY DEVELOPMENTS:

July 2019 -Verastem Oncology announced the signing of an exclusive license agreement with Sanofi for the purpose of the development and commercialization of COPIKTRA (duvelisib) in the territories of Russia and the Commonwealth of Independent States (CIS), Turkey, and the Middle East and Africa.

May 2019 -Bayer AG announced that it received the U.S. FDA Breakthrough Therapy Designation for their product offering of Aliqopa (copanlisib) for the treatment of marginal zone lymphoma, a form of non-Hodgkin lymphoma.October 2018 -The U.S. FDA announced the approval of the treatment of two rarer forms of non-Hodgkin lymphoma called Poteligeo (mogamulizumab-kpkc), which has to be administered intravenously by Kyowa Kirin, Inc.REPORT COVERAGEThe non-Hodgkin lymphoma treatment market report provides a detailed analysis of the market and focuses on key aspects such as prevalence of lymphoma - by key countries - 2018, pipeline analysis, key industry developments, regulatory scenario, by key regions, analysis of economic burden of non-Hodgkins lymphoma, new product launches, overview of emerging treatments for lymphoma, and reimbursement scenario, by key regions. Besides this, the report offers insights into the market trends and highlights key industry developments. In addition to the aforementioned factors, the report encompasses several factors that have contributed to the growth of the market over the recent years. To gain extensive insights into the market,

Report Scope & Segmentation

 

Study Period  2015-2026Base Year  2018Forecast Period  2019-2026Historical Period  2015-2017Unit  Value (USD billion)SegmentationBy TherapyImmunotherapyTargeted TherapyChemotherapyOthersBy Disease TypeB-cell LymphomaT-cell LymphomaBy Distribution Channel Hospital PharmaciesRetail PharmaciesOnline PharmaciesOthersBy GeographyNorth America (U.S. and Canada)Europe (U.K., Germany, France, Italy, Spain, Scandinavia, and Rest of Europe)Asia-Pacific (Japan, China, India, Australia, Southeast Asia, and Rest of Asia-Pacific)Latin America (Brazil, Mexico, and the Rest of Latin America)Middle East & Africa (South Africa, GCC, and the Rest of Middle East & Africa)